

Consent for Treatment with MiBo Thermoflo



MiBo Thermoflo (also “MiBo” and “MiBoFlo”) treats lipid deficiency (evaporative) dry eye which afflicts over 30 million patients in the United States. Classified as a Type II Device (with exempt) by the FDA and manufactured under strict ISO 13485. MiBo generates a stable 108 °F radiant heat source. A metallic silver delivery system carries MiBo’s therapeutic thermal energy to the lids.

MiBo Thermoflo enhances tear function through liquification of inspissated meibomian gland secretions. Repeat MiBoFlo treatments rejuvenate baseline glandular function and reduce excessive tear evaporation. MiBo improves vision and comfort by optimizing tear film lipids.

Risks are minimal with MiBo because thermal energy is tightly regulated and therapy duration is timed. The lid skin is protected by a medical grade ultrasound gel the anti-microbial properties of metallic silver. The underlying tarsal plate, eyelid musculature and conjunctiva easily tolerate the temporary physiologic temperature increase. Peer-reviewed literature and in-house assessment of both topography and endothelial cell morphology suggest MiBo preserves corneal health. Anecdotally, MiBo Thermoflo has been used safely for years in early post-operative LASIK, cataract surgery and corneal transplantation. The clinical results include enhancement of the ocular surface and improvement in tear film and corneal function.

MiBo Thermoflo patients enjoy excellent post-therapy visual acuity, but some have described temporary blurring from the release of excess meibomian gland oils. Remediation usually involves repeat MiBo and the addition of adjunctive modalities. In extreme cases, MiBo Thermoflo may be viewed as only modestly effective for some patients. Interventions with greater morbidity and higher cost may be required for optimal treatment of these patients. Corneal warpage, eyelid injury, skin damage, pain, foreign body sensation, excessive tearing, photophobia, and redness from MiBo Thermoflo have been neither described nor documented.

Supplemental modalities include systemic Omega-3s and flaxseed oil as well as topical lipid-based artificial tears. Oral Doxycycline and other tetracyclines metabolically enhance meibomian gland secretions. Lid and lash hygiene products reduce bacterial load and improve lipid quality. Intense Pulsed Light (IPL) promotes lipid metabolism through thermal effects and induced vascular modifications. Additional modalities include meibomian gland probing, eyelid exfoliation and application of Betadine and Tea Tree oil to the lid margin. These and other therapies may be added to your management regimen.

Successful management of lipid deficiency dry eye is a process often employing multiple modalities over weeks, months and sometimes years. Treatment with MiBo Thermoflo is comfortable, convenient, and frequently yields a recognizable improvement in signs and symptoms.

Practice Name / Doctor Name

Patient Signature

Date

Please confirm you understand the risks, benefits, alternatives, and limitations of this treatment. Please confirm you understand this technology is considered elective and is not covered by your medical insurance.

Your questions, comments and recommendations are welcome.
